The makers of this week’s Redefining Early Stage Investments (RESI) conference in Houston displayed two timelines that are pretty spot-on representations of how biotech funding shakes out these days.
In the past, the path forward was pretty standard – angels and family and friend rounds had exclusive domain over the earliest stages of investment. Venture capitalists moved in at the preclinical phase – though more typically joined as startups entered clinical trials. Foundations entered around then too, with private equity and corporates only taking interest when a therapeutic had already proven itself in early clinical trials.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
But things are different now. Big pharma, larger biotechs and corporate venture funds are looking at research at the earliest stages – but also coming in to buy up late stage assets. Quite the same goes for private equity, as it comes in from the ground up.
This timeline’s far more apropos:
There are claims that venture capital’s shrinking (that one’s hotly contested by venture capitalists, of course). Angels are moving into Phase 1. Friends and family are getting more actively involved. And family offices, foundations, venture philanthropy and patient advocacy groups are shaking things up among the entire funding ecosystem. The options are clearly expanding for biotech investment.
